Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Ankylosing Spondylitis (Jun 2019)

Posted by Matt Breese on Jun 14, 2019

Find me on:

According to our recent payer coverage analysis for ankylosing spondylitis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for ankylosing spondylitis treatments shows that under the pharmacy benefit, about 68% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Ankylosing Spondylitis_2Q2019Data snapshot as of Q2 2019

Trends: In April 2019, the FDA approved Samsung Bioepis Co., Ltd.'s Eticovo (etanercept-ykro) for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psorasis in people at least four years old, psoriatic arthritis and polyarticular juvenile idiopathic arthritis in children at least two years old.

To read the full Reality Check on Ankylosing Spondylitis treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing